anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Among other bodily signals, the perception of sensations arising spontaneously on the skin with no external triggers contributes to body awareness. The topic of spontaneous sensations (SPS) being quite recent in the literature, there is still a debate whether this phenomenon is elicited by peripheral cutaneous units' activity underlying tactile perception or originates directly from central mechanisms. In a first experiment, we figured that, if SPS depended on peripheral afferents, their perception on the glabrous hand should relate to the hand tactile sensitivity. On the contrary, we found no relationship at all, which led us to envisage the scenario of SPS in the absence of cutaneous units. In a second experiment, we present the case of Julie, a right-hand amputee that could perceive and report SPS arising on her phantom limb syndrome. We found that SPS distribution on the phantom limb followed the same gradient as that observed in control participants, unlike SPS perceived on the intact left hand. Those findings are crucial to the understanding of neural factors determining body awareness through SPS perception and provide insights into the existence of a precise neural gradient underlying somesthesis.
INTRODUCTION: Patients with a prolonged preoperative symptom duration (PSD) in the setting of cervical disk herniation (DH) may suffer inferior outcomes after surgical intervention. Comparison between anterior cervical diskectomy and fusion (ACDF) versus cervical disk arthroplasty (CDA) in this at-risk population has not yet been conducted.
METHODS: Patients undergoing ACDF or CDA for DH with a PSD > 180 days were selected. Six-week (6W) and final follow-up (FF) patient-reported outcome measures (PROMs) as well as magnitude of postoperative improvements (∆PROM) were compared between cohorts using multivariable linear regression. Intercohort achievement rates of minimal clinically important difference (MCID) in each PROM were compared.
RESULTS: Seventy-seven of 190 patients were in the CDA cohort. 6W Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) was superior in the CDA cohort. The ACDF cohort demonstrated notable improvements in the 6W Neck Disability Index (NDI), visual analog scale-neck pain (VAS-N), visual analog scale-arm pain (VAS-A), and 9-item Patient Health Questionnaire (PHQ-9). The CDA cohort demonstrated notable improvements in 6W PROMIS-PF, NDI, VAS-N, and VAS-A. FF VAS-A was better in the CDA cohort. The ACDF cohort demonstrated notable improvements in FF PROMIS-PF, NDI, VAS-N, and VAS-A. The CDA cohort demonstrated notable improvements in all FF PROMs. ∆PROM-6W in PROMIS-PF was greater in the CDA cohort.
CONCLUSION: Patients with prolonged PSD due to cervical DH demonstrated notable improvements in physical function, disability, pain, and mental health regardless of fusion versus arthroplasty techniques. Accounting for demographic variations, patients undergoing CDA demonstrated a greater magnitude of improvement and superior scores in physical function at the first postoperative follow-up. Rates of clinically tangible improvements in PROMs did not markedly vary by surgical procedure. Patients undergoing CDA may perceive greater early improvements to physical function compared with patients undergoing ACDF for prolonged PSD due to DH.
PIM1, the proviral integration site for Moloney murine leukemia virus, is a member of the serine/threonine protein kinase family. It is involved in many biological events, such as cell survival, cell cycle progression, cell proliferation, and cell migration, and has been widely studied in malignant diseases. However, recent studies have shown that PIM1 plays a prominent role in immunoinflammatory diseases, including autoimmune uveitis, inflammatory bowel disease, asthma, and rheumatoid arthritis. PIM1 can function in inflammatory signal transduction by phosphorylating multiple inflammatory protein substrates and mediating macrophage activation and T lymphocyte cell specification, thus participating in the development of multiple immunoinflammatory diseases. Moreover, the inhibition of PIM1 has been demonstrated to ameliorate certain immunoinflammatory disorders. Based on these studies, we suggest PIM1 as a potential therapeutic target for immunoinflammatory diseases and a valid candidate for future research. Herein, for the first time, we provide a detailed review that focuses on the roles of PIM1 in the pathogenesis of immunoinflammatory diseases.
Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
BACKGROUND: US Preventive Services Taskforce recommends against screening for COPD in asymptomatic adults due to limited evidence on the efficacy of treatments for this population. However, global and Australian guidelines recommend a case-finding approach where those with symptoms and/or risk factors, including smoking, are screened. This study aims to explore patient characteristics by time of COPD diagnosis and the effectiveness of early treatment in those with or without symptoms.
METHODS: Secondary analysis of a randomised controlled trial that included those with a pre-existing (n=130) or new diagnosis (n=142) of COPD. Those randomised to the intervention arm received an interdisciplinary intervention of smoking cessation support, home medicines review and home-based pulmonary rehabilitation, while controls received usual care. The primary outcome was health-related quality of life (HR-QoL) measured using St George's Respiratory Questionnaire. To estimate the impact of early treatment, we compared the effectiveness of treatment versus control at 6- and 12-months for the new versus pre-existing diagnosis groups, and those symptomatic versus asymptomatic or minimally symptomatic based on COPD Assessment Test score.
RESULTS: Approximately half of those newly diagnosed with COPD were already symptomatic. Early treatment in those diagnosed via case-finding had a positive non-significant impact on HR-QoL. The size of the treatment effects generally favoured the pre-existing diagnosis group when compared to case-finding and favoured those symptomatic when compared to those asymptomatic.
CONCLUSION: Despite useful insights into the impacts of case-finding and early treatments, this study, like most others, was not sufficiently powered. Further larger studies or combining sub-groups across studies are required.
PURPOSE: Inflammatory changes in epicardial (EAT) and pericardial adipose tissue (PAT) are associated with increased overall cardiovascular risk. Using routine, preinterventional cardiac CT data, we examined the predictive value of quantity and quality of EAT and PAT for outcome after transcatheter aortic valve replacement (TAVR).
MATERIALS AND METHODS: Cardiac CT data of 1197 patients who underwent TAVR at the in-house heart center between 2011 and 2020 were retrospectively analyzed. The amount and density of EAT and PAT were quantified from single-slice CT images at the level of the aortic valve. Using established risk scores and known independent risk factors, a clinical benchmark model (BMI, Chronic kidney disease stage, EuroSCORE 2, STS Prom, year of intervention) for outcome prediction (2-year mortality) after TAVR was established. Subsequently, we tested whether the additional inclusion of area and density values of EAT and PAT in the clinical benchmark model improved prediction. For this purpose, the cohort was divided into a training (n=798) and a test cohort (n=399).
RESULTS: Within the 2-year follow-up, 264 patients died. In the training cohort, particularly the addition of EAT density to the clinical benchmark model showed a significant association with outcome (hazard ratio 1.04, 95% CI: 1.01-1.07; P =0.013). In the test cohort, the outcome prediction of the clinical benchmark model was also significantly improved with the inclusion of EAT density (c-statistic: 0.589 vs. 0.628; P =0.026).
CONCLUSIONS: EAT density as a surrogate marker of EAT inflammation was associated with 2-year mortality after TAVR and may improve outcome prediction independent of established risk parameters.
The present invention relates to a novel Ledipasvir (LDV) crystal form and a preparation method thereof. Specifically, disclosed is an LDV solvate. The solvate is a solvate formed by LDV and a solvent A and/or a solvent B, wherein the solvent A is acetonitrile or acetone; and the solvent B is methyl tertiary butyl ether (MTBE). Also disclosed are a preparation method and an application of the solvate. The solvate has a high purity, a good crystallization property, and better optical stability. The preparation method is simple and the process is stable. The solvate can significantly improve quality control and industrial applications of LDV-containing drugs.
A vitamin-polymer complex comprises a styrene-maleic anhydride copolymer, which is soluble in organic solvents, and thiamine (or its thiol-type) or its esters.  The complex may contain 35-45% of thiamine, O,S-diethoxycarbonyl thiamine, S-ethoxy-carbonyl thiamine or thiamine propyl disulphide and may be prepared by reacting the thiamine or ester (in the form of the free base) with the copolymer in, e.g. acetone, ethylene dichloride or chloroform, and evaporating off the solvent.ALSO:A polymer-vitamin complex comprises a styrene-maleic anhydride copolymer, which is soluble in organic solvents, and thiamine (or its thiol-type) or its esters.  The complex may contain 35-45% of thiamine, O,S-diethoxycarbonyl thiamine, S-ethoxy-carbonyl thiamine or thiamine propyl disulphide and may be prepared by reacting the thiamine or ester (in the form of the free base) with the copolymer in e.g. acetone, ethylene dichloride or chloroform, and evaporating off the solvent.  The complex may be compounded with lactose, wheat starch, starch paste or wheat flour.ALSO:Pharmaceutical dosages, e.g. powders, granules and tablets comprise a vitamin-polymer complex, which comprises a styrene-maleic an hydride copolymer which is soluble in organic solvents and thiamine or its esters, conventional pharmaceutical additives, and riboflavin may also be present.
The present invention relates to a raditional Chinese medicine preparation for treating postpartum night sweating, which takes more than 10 traditional Chinese medicines of heterophylly falsestarwort root, dwarf lilyturf tuber, Chinese wolfberry root-bark, calcined oyster shell etc. as the raw materials. The present invention has the effects of nourishing yin, benefiting qi, promoting production of fluid and astringing sweat. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation for treating postpartum night sweating. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
The invention provides a cyclodextrin clathrate containing ligustilide. The cyclodextrin clathrate contains ligustilide and hydroxypropyl-beta-cyclodextrin. Ligustilide is coated with hydroxypropyl-beta-cyclodextrin so that the cyclodextrin clathrate is formed. A weight ratio of ligustilide to hydroxypropyl-beta-cyclodextrin is in a range of 10-20wt%. The cyclodextrin clathrate further comprises povidone K29/32. A use amount of povidone K29/32 is 10-50wt% of that of hydroxypropyl-beta-cyclodextrin. The cyclodextrin clathrate containing ligustilide can be processed to form tablets, capsules, powder or a powder injection and can be used for preparation of drugs for treating dysmenorrhoea.
Individuals with low back pain who will participate in the study will be divided into two groups. In the stabilization exercise group will be instructed to perform spinal stabilization exercises and in the yoga group will be instructed to perform yoga program consisting of breathing, relaxation and flexibility exercises. The intensity of the pain will be evaluated through visual analog scale, functional status and quality of life will be evaluated through Oswestry Disability Index(ODI), Nottingham Health Profile (NHP), respectively. The exercise adherence will evaluated Exercise Adherence Rating Scale (EARS). The time-distance characteristics of the gait will be evaluated by the OPTOGAIT photoelectric cell (OPTOGait, Microgate, Italy, 2010) and the treadmill system. Assessments will be repeated before, after the treatment, 6 and 12 month follow-up. Also,the number of back pain attacks of the individuals will be questioned and recorded.
Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
This study consisted of intervention and control groups. Thirty one patients with ILD were included in the patient's group and 37 healthy volunteers in the control group. All participants were selected from the geriatric population. Demographic and cardiopulmonary physiotherapy assessment of all participants were performed. Lung function test, maximal inspiratory and expiratory pressure and pectoralis muscle strength were measured in participants of both groups. All measurements were performed once.
General experimental design:

Pre-testing will require participants to become familiarized with performing maximal voluntary isometric contractions, as well as touring the laboratory facilities. Participants will be asked to complete dietary records for three days to determine habitual caloric intake. The experimental trial will be conducted in three phases. A baseline run-in phase (Phase 1) during which participants will consume a diet matching their estimated energy requirement to put them in a weight-stable phase. Energy requirements will be estimated using the Harris Benedict equation using an appropriate physical activity factor based on interview responses to a standard activity questionnaire. Participants will then be assigned to either the comparator group (n=10) or leucine-enriched protein food group (n=10). For the subsequent 10d (Phase 2), participants will undergo a period of step reduction (\< 1000 steps.d-1) whilst in a 500 kcal.d-1 deficit that will be adjusted for the reduced physical activity due to the step reduction. The reason for inducing an energy deficit is to mimic a situation where older individuals will be both physically inactive and 'undernourished', such as during home-bound periods of sickness or while in hospital. After completing Phase 2, participants will then return to their normal step count (from measured habitual steps pre-intervention) under energy balanced conditions for 10d that will serve as a recovery phase, Phase 3. We will complete assessments of body composition, leg lean mass, maximal voluntary isometric strength, measures of physical performance, and rate of force development will be made. Skeletal muscle biopsies will be obtained for biochemical analysis. At these time points, maximal voluntary isometric force, maximal leg press strength, a battery of physical performance measures and body composition will once again be obtained.
Hydrogels and preparation of biocompatible, in situ gelling and injectable hydrogels composed of cellulose nanofibrils and using them for tissue and organ repair and regeneration. The present invention demonstrates cellulose nanofibrils with tuned size (fibril length and distribution), high crystallinity, and high purity, variable concentration in water, and controlled charge for injectable hydrogels. The current application discovers that in situ gelling can be achieved by controlling the degree of substitution of cellulose nanofibrils through carb oxym ethyl ati on. After injection, they can form three-dimensional gels and provide attachment sites and guidance for cells to facilitate tissue and organ repair. They can be also loaded with drugs, growth factors, or signaling molecules to be delivered to targeted locations in the body and released in a controlled manner. They can be mixed with animal or human cells, including stem cells, and provide for the transport of stem cells, cells, signaling molecules, and/or active components to injury sites.
PURPOSE:A remedy and preventing agent for senile dementia, of symptoms, e.g. reduction in the intelligence, disorientation, extreme decrement of retention and memory, nycterine dromomania, etc., containing dimethyl sulfoxide as an active constituent. CONSTITUTION:A remedy and preventing agent for senile dementia containing dimethyl sulfoxide as an active constituent. The dimethyl sulfoxide is a compound used as a solvent, and known to have the pharmacological actions, e.g. permeation promoting, local anesthetic, sedative and inflammatory actions, inhibitory action on bacterial growth, cooling, temporary diuretic and effect enhancing actions on a drug used together. The resultant pharmaceutical can be administered in a formulated concentrate or an optional dosage form, through various routes, e.g. an injection, soft capsule, ointment or suppository.
Subjects who meet the following inclusion criteria: 1) Severe aortic stenosis. 2) Age \> 65 years for male and \>70 years for female. 3) Increased left ventricular wall thickness ≥14 mm. 4) Blood pressure ≤ 140/90 mmHg and at least 1 major or ≥ 2 minor criteria. Major criteria: a) Carpal tunnel syndrom; b) Non-traumatic rupture of the biceps tendon; c) NT-proBNP \> 1000 pg/ml; d) hs Troponin value above the 99th percentile without dynamic changes (≤ 20%). Minor criteria: a) Diastolic dysfunction (at least grade 2, E' \< 10 cm/s); b) Sinus bradycardia/AV block/pacemaker; c) Atrial fibrillation.
The signs and symptoms of overdosage are those of hyperthyroidism (see and ). In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures have occurred in a child ingesting 18 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium. PRECAUTIONSADVERSE REACTIONS
Invention herewith described refers to the synthesis, characterisation and pharmacological properties of the bioactive copper(II)-ion complexes with pullulan and its derivatives. The complex compounds of Cu(II)-ions with oligosaccharides of pullulan (Mw 1.000-80.000 gmol-1) and its derivatives, primarily reduced and oxidized pullulan (Mw 1.000-25.000 gmol-1), are synthesized, physico-chemically characterized and pharmacologically investigated. The synthesis procedure is characterized by technical simplicity and economy. Following the suggested procedure, pullulan is first prepared as a ligand for the complex synthesis including its depolymerisation and characterization (RG, MW, [η] determination) and then the reduction or oxidation of the adequate oligomers. The complex synthesis is performed at the boiling temperature at pH 7-8 in the presence of Cu(II)-ion salt solution. The obtained complex is then subjected to the subsequent physico-chemical purification processes and prepared for structural and pharmacological investigations. Based on the standardized aqueous solution of Cu(II)-ion complex with oligosaccharides of pullulan, the pharmacologically investigated pharmaceutical preparation is prepared, which can be used to prevent the condition resulting from copper deficiency (hypocupremia), as well as in the prevention and treatment of various types of anaemia (individually or combined with bio metal preparations), primarily in veterinary medicine and later, with some corrections, in human medicine.
The invention relates to antibody-drug conjugates (ADC) that are potentiated by co-administration of the ADC with a moiety comprising covalently linked saponin. The invention also relates to antibody-oligonucleotide conjugates (AOC) that are potentiated by co-administration of the AOC with a moiety comprising covalently linked saponin. The invention also relates to ADCs and AOCs which are conjugated with a saponin via a covalent linker. The invention further relates to an effector moiety such as a toxin or an antisense oligonucleotide such as for example a BNA, conjugated with a saponin via a covalent linkage. The invention also relates to a BNA covalently conjugated with a targeting moiety such as an antibody. The invention also relates to therapeutic combinations comprising a first pharmaceutical composition comprising a conjugate of a cell-targeting moiety such as an antibody and an antisense oligonucleotide such as a BNA covalently bound thereto, and comprising a second pharmaceutical composition comprising either a free saponin, or a conjugate of a cell-targeting moiety such as an antibody with a saponin covalently linked thereto. Furthermore, the invention relates to any of these conjugates or therapeutic compositions or therapeutic combinations, for use as a medicament. The invention also relates to any of these conjugates or therapeutic compositions or therapeutic combinations, for use in a method for the treatment or the prophylaxis of a cancer. Finally, the invention relates to methods for producing any of these conjugates of the invention.
In an environment where it is beneficial for chronic health care patients to receive individualized attention on a daily basis, a health care network ( 10 ) is provided. Each patient receives a user interface device ( 12 ) such as a set top box for accessing the network ( 10 ). Based on the patient's health care history, a nurse or other health care professional interfaces with a server ( 22 ) and constructs a care plan specific to that patient by filling out appropriate sections of a care plan template. An itinerary arrangement processor ( 32 ) organizes content gleaned from the patient's care plan and constructs a serially arranged itinerary for the patient to experience each day. The patient logs on to the network ( 10 ) and is immediately presented with the day's itinerary, without having to navigate any menus. Resultantly, the patient will have an easier experience, and will not miss any material.